Amrize
AMRZ
36.39
-0.89
-2.39%
Amrize
US · AMRZ
#911 by market cap
Listed 2025
36.39
-0.89
-2.39%
Live - 5344 symbols - heartbeat 26s ago
· 2026-10-08 07:35
Pre-market
35.93
-1.26%
After-hours
36.39
0.00%
Overnight
35.90
-1.35%
- Market cap
- 19.90B
- P/E (TTM)i
- 16.20
- P/Bi
- 1.55
- EPSi
- 2.14
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on AMRZ?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.98, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 5 years
Latest year +0.95% YoY
Margins
- Gross margin
- 25.68%
- Operating margin
- 16.13%
- Net margin
- 10.03%
Key ratios & quality
- Enterprise valuei
- 23.50B
- PEG ratioi
- 7.15
- Altman Z-Scorei
- 1.98
PEG uses trailing P/E against the 3-year net income growth rate (2.26%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 8.13B | 10.73B | 11.68B | 11.70B | 11.82B |
| Gross profit | 1.82B | 2.47B | 2.77B | 3.07B | 3.03B |
| Selling & admin expenses | 552.00M | 752.00M | 898.00M | 944.00M | 1.13B |
| Research & development | -- | -- | -- | -- | -- |
| Operating profit | 1.27B | 1.72B | 1.87B | 2.13B | 1.91B |
| Pretax profit | 1.12B | 1.46B | 1.30B | 1.63B | 1.50B |
| Tax | 284.00M | 366.00M | 361.00M | 368.00M | 326.00M |
| Net profit | 843.00M | 1.11B | 955.00M | 1.27B | 1.18B |
| Basic EPS | 2 | 2 | 2 | 2 | 2 |
| Diluted EPS | 1.52 | 2.00 | 1.73 | 2.31 | 2.14 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.08B | 3.22B | 3.68B | 2.84B | 2.18B | 3.49B |
| Gross profit | 222.00M | 941.00M | 1.09B | 760.00M | 211.00M | 993.00M |
| Selling & admin expenses | 239.00M | 286.00M | 312.00M | 278.00M | 292.00M | 283.00M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -17.00M | 655.00M | 774.00M | 482.00M | -81.00M | 710.00M |
| Pretax profit | -133.00M | 537.00M | 689.00M | 392.00M | -145.00M | 621.00M |
| Tax | -46.00M | 122.00M | 150.00M | 100.00M | -27.00M | 146.00M |
| Net profit | -87.00M | 416.00M | 543.00M | 298.00M | -118.00M | 476.00M |
| Basic EPS | 0 | 1 | 1 | 1 | 0 | 1 |
| Diluted EPS | -0.16 | 0.75 | 0.98 | 0.54 | -0.21 | 0.86 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | -- | 3.16B | 3.94B | 4.78B | 4.68B |
| Cash & ST investments | -- | 351.00M | 1.11B | 1.59B | 1.92B |
| Inventory | -- | 1.23B | 1.31B | 1.45B | 1.55B |
| Total assets | -- | 20.67B | 23.05B | 23.81B | 24.25B |
| Total current liabilities | -- | 2.25B | 2.44B | 2.55B | 2.86B |
| Short-term debt | -- | 521.00M | 319.00M | 348.00M | 580.00M |
| Long-term debt | -- | 7.62B | 8.64B | 8.50B | 4.94B |
| Total liabilities | -- | 12,460,000,000.00 | 13,844,000,000.00 | 13,891,000,000.00 | 10,995,000,000.00 |
| Total equity | -- | 8.21B | 9.20B | 9.91B | 13.25B |
| Retained earnings | -- | -- | -- | 0 | 902.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.22B | 4.33B | 4.57B | 4.68B | 4.28B | 4.58B |
| Cash & ST investments | 40.00M | 601.00M | 826.00M | 1.92B | 1.10B | 729.00M |
| Inventory | 1.60B | 1.64B | 1.51B | 1.55B | 1.57B | 1.55B |
| Total assets | 22.31B | 23.78B | 24.04B | 24.25B | 24.27B | 24.60B |
| Total current liabilities | 1.94B | 3.14B | 3.15B | 2.86B | 3.05B | 4.15B |
| Short-term debt | 228.00M | 1.17B | 1.11B | 580.00M | 1.36B | 2.08B |
| Long-term debt | 5.04B | 5.26B | 4.93B | 4.94B | 4.94B | 4.24B |
| Total liabilities | 9,838,000,000.00 | 11,349,000,000.00 | 11,137,000,000.00 | 10,995,000,000.00 | 11,181,000,000.00 | 11,745,000,000.00 |
| Total equity | 12.47B | 12.43B | 12.90B | 13.25B | 13.09B | 12.86B |
| Retained earnings | -- | 59.00M | 601.00M | 902.00M | 785.00M | 997.00M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 1.49B | 1.99B | 2.04B | 2.28B | 2.21B |
| Depreciation & amortization | 712.00M | 788.00M | 851.00M | 875.00M | 900.00M |
| Free cash flow | 1.10B | 1.50B | 1.41B | 1.64B | 1.42B |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- |
| Ending cash balance | 399.00M | 351.00M | 1.11B | 1.59B | 1.92B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -856.00M | 415.00M | 845.00M | 1.80B | -896.00M | 421.00M |
| Depreciation & amortization | 215.00M | 222.00M | 223.00M | 240.00M | 233.00M | 254.00M |
| Free cash flow | -1.07B | 178.00M | 662.00M | 1.65B | -1.17B | 173.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 574.00M | 601.00M | 826.00M | 1.92B | 1.10B | 729.00M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | 13.50 | 10.53 | 12.61 | 8.92 |
| ROA %i | -- | 5.36 | 4.20 | 6.09 | 4.96 |
| ROIC %i | -- | 7.67 | 7.53 | 8.74 | 7.79 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.90 | 15.92 | 15.73 | 18.13 | 16.17 |
| FCF / sales %i | 13.50 | 13.98 | 12.04 | 14.01 | 12.02 |
| Current ratioi | -- | 1.40 | 1.61 | 1.87 | 1.64 |
| Quick ratioi | -- | 0.78 | 1.03 | 1.25 | 1.06 |
| Debt / assetsi | -- | 41.90 | 41.32 | 40.09 | 26.16 |
| LT debt / equityi | -- | 99.15 | 100.02 | 92.75 | 43.47 |
| Interest coveragei | 7.26 | 6.89 | 3.13 | 7.03 | 4.62 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 12.90 | 3.28 |
| Net income CAGR (3Y) %i | -- | -- | -- | 14.85 | 2.26 |
| FCF CAGR (3Y) %i | -- | -- | -- | 14.31 | -1.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 11.29 | 10.70 | 11.65 | 8.92 | 9.04 | 9.76 |
| ROA %i | 6.31 | 5.60 | 5.51 | 4.96 | 4.96 | 5.10 |
| ROIC %i | 8.71 | 7.94 | 7.62 | 7.79 | 7.44 | 7.58 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 17.54 | 16.89 | 16.10 | 16.17 | 15.53 | 15.56 |
| FCF / sales %i | 11.64 | 9.91 | 11.97 | 12.02 | 11.07 | 10.79 |
| Current ratioi | 1.67 | 1.38 | 1.45 | 1.64 | 1.40 | 1.10 |
| Quick ratioi | 0.74 | 0.79 | 0.93 | 1.06 | 0.80 | 0.67 |
| Debt / assetsi | 26.71 | 30.16 | 28.66 | 26.16 | 29.25 | 29.07 |
| LT debt / equityi | 45.96 | 48.29 | 44.76 | 43.47 | 43.84 | 39.41 |
| Interest coveragei | 8.06 | 6.83 | 7.74 | 4.62 | 5.07 | 5.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Building materials is the largest reported line at 69.98% of revenue, across 2 reported segments.
- Building Envelope follows at 30.02%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Building materials69.98%
Building Envelope30.02%
Quote time 2026-10-08 07:35:41 · For reference only, not investment advice and not tailored to your situation.